Skip to main content

Advertisement

Table 1 Plasma levels of total PSA, PSA subforms and hK2 in cases and controls at baseline venipuncture. Data are given as median (interquartile range). For illustrative purposes, we show data for cases known to be less than T3 and M0 at diagnosis (88 cases had data missing for either stage or metastases and were not T3, T4 or M+). As would be expected, controls matched with non-advanced cancers had almost identical markers levels to the controls matched with advanced cases (data not shown).

From: Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

Marker Advanced cancer n= 161 Controls (matched with advanced cases) n= 436 Non-advanced cancer n= 213
Total PSA (ng/ml) 1.22 (0.67, 2.42) 0.54 (0.36, 0.78) 0.98 (0.61, 1.56)
Free PSA (ng/ml) 0.35 (0.22, 0.67) 0.18 (0.12, 0.26) 0.30 (0.19, 0.45)
Complexed PSA (ng/ml) 0.81 (0.41, 1.64) 0.32 (0.20, 0.51) 0.62 (0.38, 1.04)
Free to total PSA ratio (%) 29.0 (24.2, 33.7) 32.7 (28.3, 37.2) 30.5 (26.2, 33.7)
Human kallikrein 2 (ng/ml) 0.039 (0.027, 0.055) 0.033 (0.023, 0.044) 0.037 (0.028, 0.053)